Bougie Sleeve Trial
- Conditions
- Morbid Obesity
- Interventions
- Procedure: Laparoscopic sleeve gastrectomy using 48-Fr bougieProcedure: Laparoscopic sleeve gastrectomy using standard care bougie
- Registration Number
- NCT02937649
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Brief Summary
Staple-line leak is the most frequent and incapacitating complication after laparoscopic sleeve gastrectomy (LSG). The aim of this prospective randomized trial is to compare the staple-line leak rate after LSG according to the use of a standard bougie calibre (34, 36 or 38 Fr) or 48-Fr, assuming that a higher diameter is correlated with a lower risk of leak, without lowering long-term weight loss.
- Detailed Description
Laparoscopic sleeve gastrectomy (LSG) has become an increasing bariatric procedure. The most common complication is gastric leak from the staple line, observed in approximately 3% of cases, and can result in long and incapacitating treatment. The diameter of the bougie used to calibrate the remnant stomach could impact the rate of gastric leak, a higher diameter being correlated with a lower risk of leak, without lowering long-term weight loss.
The aim of this prospective randomized trial is to compare the outcomes of LSG according to the use of a standard care bougie calibre or 48-Fr on postoperative gastric leak and mid-term weight loss.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1658
- Patients between 18 and 70 years
- Sleeve gastrectomy as a primary bariatric procedure
- Body Mass Index (BMI) > 40 kg/m² or > 35 kg/m² associated with at least one comorbidity susceptible to improve after surgery (including arterial hypertension, obstructive sleep apnea syndrome and other severe respiratory disorders, severe metabolic disorders, particularly type 2 diabetes, incapacitating osteo-articular disorders, non alcoholic steatohepatitis)
- Decision for intervention after multidisciplinary discussion
- Written informed consent
- Previous upper abdominal surgery (cholecystectomy excepted)
- ASA (American Society of Anesthesiologists) score > 3
- Ongoing pregnancy or breast feeding
- Esophagus pathology or disorder (esophageal varices, esophageal diverticula, esophageal tumors, esophageal strictures)
- Coagulation disorder
- Patient not covered by social security service and patient on AME
- Patient under legal guardianship and trusteeship
- Patient with known silicon allergy (calibration bougie contains medical silicon)
- More generally, all other contraindications to the use of esophageal bougie MID-TUBE that have been the subject of a scientific paper or have been identified by the practitioner or practitioners
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Laparoscopic sleeve gastrectomy using 48-Fr bougie Laparoscopic sleeve gastrectomy using 48-Fr bougie Patients will undergo laparoscopic sleeve gastrectomy with a 48-Fr (16 mm) bougie Laparoscopic sleeve gastrectomy using standard care bougie Laparoscopic sleeve gastrectomy using standard care bougie Patients will undergo laparoscopic sleeve gastrectomy with a standard care bougie (34, 36 or 38-Fr)
- Primary Outcome Measures
Name Time Method Postoperative gastric leak rate 30 days following the procedure Postoperative gastric leak rate during the first month following the procedure will be proven either on:
* Morphologic examination (with contrast ingestion)
* Blue dye test during surgical reintervention or postoperative course
* Contrast opacification during endoscopy
- Secondary Outcome Measures
Name Time Method Postoperative morbidity rate 90 days following the procedure Postoperative morbidity rate will be calculated regarding any complication occurring 90 days following the procedure.
Short-term weight loss At 3 and 6 months after the procedure Short-term weight loss will be assessed by calculation of excess weight loss at 3 and 6 months after the procedure.
Mid-term weight loss At 1 and 2 years after the procedure Mid-term weight loss will be assessed by calculation of excess weight loss at 1 and 2 years after the procedure.
Quality of life related to health At 3 months, 6 months, 1 year and 2 years after the procedure Quality of life related to health will be assessed at 3 months, 6 months, 1 year and 2 years after the procedure with the validated GIQLI scale (Gastro Intestinal Quality of Life Index)
Trial Locations
- Locations (12)
Hôpital Ambroise Paré
🇫🇷Boulogne-Billancourt, France
Hôpital Côte de Nacre CHU de Caen
🇫🇷Caen, France
CHU Antoine Béclère
🇫🇷Clamart, France
Centre hospitalier Intercommunal de Créteil
🇫🇷Créteil, France
Hôpital MICHALLON, CHU de Grenoble
🇫🇷La Tronche, France
Hôpital Dupuytren - Limoges
🇫🇷Limoges, France
Clinique de l'Yvette
🇫🇷Longjumeau, France
Service de chirurgie générale et digestive, œsogastrique et bariatrique - Hôpital Bichat
🇫🇷Paris, France
CHI - Centre Hospitalier Poissy/Saint-Germain-en-Laye
🇫🇷Poissy, France
CH Saint-Denis
🇫🇷Saint-Denis, France
Clinique Mutualiste Chirurgicale
🇫🇷Saint-Étienne, France
Hôpitaux de Brabois
🇫🇷Vandœuvre-lès-Nancy, France